GlassScriptPhysician profile
Willem Vanheeckeren
NPI 1306931761
$2,856.21
in general payments reported to CMS, 2019-2025
40 companies · $54.20 in 2025
The $54.20 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,453 · 2020: $240 · 2021: $108 · 2025: $54.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $54.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $54.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $1,356.16 | 2019 | |
| Eisai INC. | $137.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.58 | 2019-2020 | |
| Genzyme Corporation | $101.09 | 2019-2020 | |
| Amgen INC. | $97.02 | 2019-2021 | |
| Tesaro, INC. | $86.33 | 2019 | |
| Merck Sharp & Dohme LLC | $64.38 | 2019-2020 | |
| Celgene Corporation | $56.62 | 2019-2020 | |
| Glaxosmithkline, LLC. | $56.51 | 2020-2025 | Ojjaara |
| Exelixis INC. | $52.70 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.13 | 2019 | |
| Astellas Pharma US INC | $48.08 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $46.19 | 2019 | |
| Genentech USA, INC. | $45.73 | 2019-2025 | Polivy |
| Astrazeneca Pharmaceuticals LP | $41.27 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willem Vanheeckeren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.